BioSeeker Drug Pipeline Updates
Drug Pipeline Update products from BioSeeker Group contain detailed, and world-wide covering, drug pipeline information for a selected cancer indication area(s) or mechanism of action area(s). A typical drug profile in Drug Pipeline Update reports on:
- Drug Name & Synonyms
- Investigator(s)
- Indication(s)
- Developmental Stage(s)
- Mechanism(s)
- Target(s)
- Clinical Development
- Developmental History
- Scientific Data
- Patents
- In/Out-licensing
- Collaborations
- Analysts Comments
Our Drug Pipeline Update products serve executives in the pharmaceutical, biotech, and financial industries. BioSeeker provides an unbiased, accurate, independent approach to pipeline analysis, for competitive, partnering or investment purposes.
Software Application
BioSeeker delivers Drug Pipeline Update as an intelligent software application (see system requirements). This software requires no installation:
- Drug Pipeline Update is fitted into a software application (downloadable), for your intelligent usage
- Smart application funtions which makes it easy to use and navigate by
- Multiple search and sort functions included
- Drug data is linked to search engines like Google and PubMed
- Direct links to web pages from inside the application
- Found information is easily shared with others over email, file export or in print
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/outlicensing strategy work
- Fast and easy way of tracking drugs using search engines; with just one click you may search the entire Internet or PubMed for any drug with all its synonyms.
System Requirements
- Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Available Drug Pipeline Updates
-
Hematological Cancers Drug Pipeline Update 2012
€1,999.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 374 companies plus partners who are today developing 584 hematological cancer drugs in 1169 developmental projects in cancer across 300 different targets. In addition, there are 7 suspended drugs and another 184 drugs where development has been ceased. Learn More -
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 197 companies plus partners who are today developing 221 T cell receptor pathway targeting drugs in 731 developmental projects in cancer across 130 different targets. In addition, there are 7 suspended drugs and another 129 drugs where development has been ceased. Learn More -
Cytokine Therapy in Oncology Drug Pipeline Update 2012
€999.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 82 companies plus partners who are today developing 104 cytokine drugs in 204 developmental projects in cancer across 20 different targets. In addition, there are 2 suspended drugs and another 7 drugs where development has been ceased. Learn More -
Immunotherapy in Oncology Drug Pipeline Update 2012
€2,450.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 469 companies plus partners who are today developing 871 cancer immunotherapy drugs in 1970 developmental projects in cancer across 337 different targets. In addition, there are 16 suspended drugs and another 343 drugs where development has been ceased. Learn More -
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 144 companies plus partners who are today developing 203 Kit receptor pathway targeting drugs in 694 developmental projects in cancer across 114 different targets. In addition, there are 2 suspended drugs and another 94 drugs where development has been ceased. Learn More -
FSH Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 157 companies plus partners who are today developing 178 FSH pathway targeting drugs in 610 developmental projects in cancer across 108 different targets. In addition, there are 2 suspended drugs and another 101 drugs where development has been ceased. Learn More -
Radiation Therapy in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 318 companies plus partners who are today developing 335 radiation therapy drugs in 663 developmental projects in cancer across 172 different targets. In addition, there are 6 suspended drugs and another 123 drugs where development has been ceased. Learn More -
Lymphoma Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 208 companies plus partners who are today developing 293 lymphoma drugs in 406 developmental projects in cancer across 182 different targets. In addition, there are 2 suspended drugs and another 80 drugs where development has been ceased. Learn More -
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2012
€999.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 89 companies plus partners who are today developing 88 Wnt pathway targeting drugs in 273 developmental projects in cancer across 97 different targets. In addition, there is 1 suspended drug and another 45 drugs where development has been ceased. Learn More -
RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 164 companies plus partners who are today developing 192 RANKL pathway targeting drugs in 643 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 104 drugs where development has been ceased. Learn More -
Neuroendocrine Tumors Drug Pipeline Update 2012
€999.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 50 companies plus partners who are today developing 60 neuroendocrine tumor drugs in 83 developmental projects in cancer across 54 different targets. In addition, another 5 drugs where development has been ceased. Learn More -
Lung Cancer Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 333 companies plus partners who are today developing 426 lung cancer drugs in 507 developmental projects in cancer across 243 different targets. In addition, there are 9 suspended drugs and another 189 drugs where development has been ceased. Learn More -
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2012
€499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 40 companies plus partners who are today developing 31 Hedgehog pathway targeting drugs in 123 developmental projects in cancer across 40 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More -
TSH Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 135 companies plus partners who are today developing 182 TSH pathway targeting drugs in 551 developmental projects in cancer across 121 different targets. In addition, there are 2 suspended drugs and another 81 drugs where development has been ceased. Learn More -
Brain Cancer Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 183 companies plus partners who are today developing 186 drugs targeting brain cancer in development. across 131 different targets. In addition, there are 3 suspended drugs and another 68 drugs where development has been ceased. Learn More

